Ifinatamab Deruxtecan Biologics License Application for Certain Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer Voluntarily Withdrawn
BLA FilingrejectedIfinatamab DeruxtecanNegative
AI Analysis
Summary
Daiichi Sankyo and Merck voluntarily withdrew the Biologics License Application for Ifinatamab Deruxtecan seeking accelerated approval for previously treated extensive-stage small cell lung cancer in the U.S.
Outcome Details
Biologics License Application voluntarily withdrawn
Importance:8/10
Sentiment:
-0.80
BLA withdrawalsmall cell lung canceraccelerated approvaloncology
Read the original article
Published by Drugs.com Clinical Trial Results on September 25, 2026 9:09 PM